HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM)

NCT ID: NCT07260604

Last Updated: 2025-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-10-15

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is not difficult to imagine that leaking urine affects life in many contexts. Unfortunately, it is everyday life for far too many people in our society. According to the National Board of Health and Welfare, incontinence primarily affects older people, and both women and men are vulnerable. In Sweden, just over 530,000 people over the age of 65 have problems and almost 80 percent of all people in special housing have such urine leakage that they need to use incontinence aids. First-line treatment for women with incontinence is local estrogen and pelvic floor training. Surgery may also be considered if this treatment does not provide sufficient effect.

A new type of treatment for stress, urge and mixed incontinence is now on the market, High-Intensity Focused Electromagnetic (HIFEM®) treatment. This involves electromagnetic stimulation that causes contractions in the pelvic floor muscles. The treatment is not painful or invasive and the patient sits clothed in the treatment chair. In Sweden, HIFEM® is mainly available outside of traditional healthcare and is very expensive. It is also often given by unauthorized actors.

We are now planning a study whose purpose is to evaluate the effect of HIFEM® on women over 65 years of age with stress incontinence. A group of 100 women will be randomized to:

1. Standard treatment, i.e. physiotherapy-led pelvic floor training
2. As above with the addition of 10 treatments of 30 minutes with HIFEM®.

The evaluation will be carried out regarding leakage, need for incontinence aids and pelvic floor strength immediately and six months after the intervention. The women will also rate their incontinence symptoms, physical activity level, physical function and quality of life. A group will also be interviewed about their experiences of living with incontinence and the treatment. Before the study start, a case study will be performed in which 10 women will be included. They will receive 10 treatments and measure, with the same outcomes, the effects.

Alternative treatment methods are important to meet the care needs we have today but also in the future. If treatment with HIFEM® can be effective for women over 65, it could, in addition to reducing incontinence problems and the consequences of these problems, also lead to reduced costs for society regarding care and incontinence products, as well as reduced environmental impact.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence (UI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Before the RCT, a case study will be performed. In addition, a qualitative study part is included in the RCT
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Single Blind (Outcomes Assessor) - physiotherapist performing muscle strength assessment blinded to allocation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A - Standard Pelvic Floor Training

* Active pelvic floor muscle training led by a physiotherapist, following standard practice.
* Includes individualized advice and daily Kegel exercises to increase endurance and strength.

Group Type ACTIVE_COMPARATOR

Pelvic Floor exercises

Intervention Type OTHER

Pelvic floor training according to national guidelines

Arm B - Pelvic Floor Training + HIFEM

* Same physiotherapist-led training as Arm A.
* In addition: HIFEM treatment with Emsella chair.
* 10 sessions, 30 min each, over 5 weeks (2 sessions per week).
* Standardized stimulation delivered while seated, fully clothed, in a nurse-led clinic in Gothenburg.

Group Type EXPERIMENTAL

Pelvic floor training as described in point a above, with the addition of HIFEM.

Intervention Type DEVICE

Pelvic floor training with the addition of HIFEM. The treatment will be administered over 8-10 sessions of 30 minutes each, over a period of 4-6 weeks, with two sessions per week. During treatment, the women will sit fully clothed in a treatment chair and receive standardized stimulation of the pelvic floor muscles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pelvic floor training as described in point a above, with the addition of HIFEM.

Pelvic floor training with the addition of HIFEM. The treatment will be administered over 8-10 sessions of 30 minutes each, over a period of 4-6 weeks, with two sessions per week. During treatment, the women will sit fully clothed in a treatment chair and receive standardized stimulation of the pelvic floor muscles.

Intervention Type DEVICE

Pelvic Floor exercises

Pelvic floor training according to national guidelines

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 65-85 ears
* Having daily stress incontinence requiring use of incontinence aids.
* Living in ordinary housing without home (health-) care
* Being physically active and can move independently both indoors and outdoors.
* Being able to give independent informed consent in speech and writing
* To understand and follow instructions in one of following languages Swedish, Arabic, French, and/or English

Exclusion Criteria

* -Ongoing coached pelvic floor training
* Heart disease where treatment is contraindicated
* Lung disease with chronic cough
* Pacemaker, defibrillator, neurostimulator, medication pump, and implanted devices in the head or spinal cord
* Electronic or metal implants in the abdomen, hips, or knees
* Epilepsy
* Ongoing cancer
* Stoma or abdominal hernia
* Ongoing treatment with anticoagulants such as warfarin, medicines affecting the bladder such as muscarin receptor antagonist, diuretics and local oestrogen which affect the bladder and urine production.
* infection, fever, bleeding, or pain in the lower abdomen
* Skin diseases or any skin sensitivity
* BMI exceeding 30 kg/m2
Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Göteborg University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gothenburg university

Gothenburg, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Monika Fagevik Olsén, Professor

Role: CONTACT

+46 766-185713

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

MOnika Fagevik Olsén, Professor

Role: primary

+46 766185713

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FoU in Sweden 284879

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tele-rehabilitation for Women With Urinary Incontinence
NCT06161324 ENROLLING_BY_INVITATION NA